07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Macrophage stimulating protein (MSP; MST1); serine/threonine kinase 3 (STK3; MST2)

Gastrointestinal disease INDICATION: Colitis; hepatic; liver fibrosis Mouse studies suggest combined inhibition of MSP and STK3 could help treat colitis, liver damage and liver fibrosis. In a mouse model of chemical-induced colitis, a dual MSP/STK3...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Illumina, Oxford Nanopore genomics news

Illumina filed two concurrent lawsuits against Oxford Nanopore alleging that the nanopore-based sequencing company’s MinION and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina alleged that MinION and PromethION infringe on U.S....
01:07 , Feb 25, 2016 |  BC Extra  |  Company News

Illumina suing Oxford Nanopore

Illumina Inc. (NASDAQ:ILMN) filed two concurrent lawsuits against nanopore-based sequencing company Oxford Nanopore Technologies Ltd. (Oxford, U.K.) alleging that Oxford Nanopore's MinION and PromethION devices infringe patents to which Illumina has exclusive rights. Illumina is...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Manchester Science Parks (MSP) pharmaceuticals news

AstraZeneca will sell its facility in Alderley Park, U.K., to MSP, a public-private science park operator. The pharma expects to complete the sale of the facility - which was focused on small molecule R&D -...
07:00 , May 30, 2013 |  BC Innovations  |  Cover Story

RON's new role

A Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response. 1 The findings build a case for directed drug discovery efforts against the target, which...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

MDxHealth, Takara Bio deal

Takara received a non-exclusive, worldwide license to use MDxHealth's methylation specific PCR ( MSP ) technology as part of its research tools which are used to identify methylation patterns in cancer. MDxHealth will receive an...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Serine/threonine kinase 4 (STK4; MST1); Serine/threonine kinase 3 (STK3) (MST2); SAV1 salvador family WW domain containing protein 1 (SAV1) Studies in mice suggest...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Clinical News

Stool-based colorectal cancer assay diagnostic data

A preliminary analysis of stools from the first 147 patients enrolled in a biomarker study showed that 2 ONCO methylation genes detected early stage colorectal cancer with 86% sensitivity and 96% specificity. The trial is...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Company News

Exact Sciences, OncoMethylome deal

ONCO received a non-exclusive license to EXAS's DNA stabilization, isolation and extraction technology to develop and market stool-based diagnostics to detect colorectal cancer. EXAS is eligible for royalties. Separately, ONCO will supply reagents to EXAS...
07:00 , Jun 12, 2006 |  BioCentury  |  Finance

Tysabri chronicles

Tysabri chronicles...